Discover AstraZeneca's financial report on Calquence's EU approval for untreated CLL, highlighting significant trial results and market potential.
AstraZeneca's SEC report reveals the discontinuation of the CAPItello-280 trial for mCRPC. Discover the reasons, trial details, and future strategies in prostate cancer treatment.
Discover the pivotal findings from AstraZeneca's DESTINY-Breast09 trial, showcasing Enhertu's potential in HER2-positive metastatic breast cancer and its impact on patient care.
Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.
Evaxion Biotech A/S files Form 6-K on Feb 25, 2025, announcing an extension of its EVX-01 cancer vaccine trial. Key for growth and market positioning in biotech.
Explore Cogent Biosciences' Q4 2023 financial results, highlighting significant net losses, cash position, and strategic recommendations for investors.
Explore AstraZeneca's SERENA-6 trial results on camizestrant, showing significant PFS improvement for HR-positive breast cancer. Discover its market potential and safety profile.
Explore AstraZeneca's 6-K filing detailing Imfinzi's Phase III MATTERHORN trial results, showing significant improvements in event-free survival for gastric cancer patients.
AstraZeneca's Form 6-K details the CALYPSO trial results for eneboparatide, indicating significant potential for treating chronic hypoparathyroidism. Key findings and next steps outlined.
Discover AstraZeneca's groundbreaking approval of Imfinzi for muscle-invasive bladder cancer, backed by clinical trials showing improved survival rates and reduced recurrence.
Explore Travere Therapeutics' Q4 2024 Financial Report highlighting $233M in revenue and increased net losses. Insights and hold recommendation for investors.
Explore IDEAYA Biosciences' FY 2024 financial report highlighting revenue drop, R&D surge, and strategic partnerships. Recommended investor stance: Hold.